Kainos' business model is to generates revenue through licensing-out IP(Intellectual Properties)
to global and local pharma and biotech companies. So research collaboration through strategic
partnering using our core competitiveness in medicinal chemistry, which is necessary
for creating the synergy for successful global drug development. We have signed a
licensing and collaboration agreement for global drug development
with Hanmi pharm Co., Ltd. in December 2012.

We are seeking collaboration partners
for successful drug development based on our business model and R&D strategy.